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Background:  Inflammatory markers are extensively studied in ACS because of the key role of inflammation in atherogenesis and plaque rupture. 
Among them, Myeloperoxidase (MPO) is regarded as a potential useful diagnostic marker of disease in Acute Coronary Syndrome as neutrophil 
activation is one of the very first steps in inflammation. However in patients (pts) with chest pain, recent studies provided conflicting results. We 
evaluated MPO for early diagnosis of ACS, in comparison with conventional and high sensitivity Troponin assays.
Methods:  452 consecutive all comers subjects with chest pain, admitted to ED within 12 hours from the onset of pain were enrolled. Serum levels 
of conventional cTnT (cTnT), high sensitivity Troponin T (hs-TnT), hs-TnI and MPO were measured from baseline samples. EKG and previous history 
of ACS were obtained in all pts. MPO was analyzed as quartiles; diagnostic accuracy of all biomarkers was evaluated by constructing Receiver-
Operating Characteristic (ROC) curve and calculating Area Under Curve (AUC).
Results:  Fifty-one pts (9% of overall population) were discharged with a diagnosis of ACS according to current guidelines. Diagnostic accuracy was 
similar between different Troponin Assays: AUC=0,80 for cTnT; AUC=0,81 for hs-TnT (Roche) and AUC=0.82 for hs-TnI (LOCI, Siemens). However AUC 
of MPO was much lower compared to others biomarkers (AUC=0,50): MPO was not different between ACS and non- ACS pts [pM/L, median-range 
ACS:373 (143-2926); non-ACS: 374 (35-6627) p=0.66].
Conclusions:  In our heterogeneous chest pain population, MPO does not carry relevant diagnostic information. Troponins assessed with both 
conventional and high-sensitivity assay have a similar diagnostic accuracy in our population.
